Dr. Sayad joined Karyopharm in 2018 and is responsible for overseeing the company’s Medical Affairs organization, including Scientific Communication, Medical Information, and the U.S. and European Medical Science Liaisons (MSLs) teams.
Dr. Sayad began his career at Eli Lilly and Company within the commercial organization and helped drive the successful launches of the neuroscience blockbusters Zyprexa®, Cymbalta®, and Strattera®. He then joined the strategic management consulting firm Campbell Alliance and worked across multiple practice areas, with a strong focus in Medical Affairs, and led engagements for numerous biotech clients. Joining Onyx Pharmaceuticals in 2011, Dr. Sayad led the Medical Strategy and Operations team and supported the scientific development and subsequent approval and launch of Kyprolis® for relapsed refractory multiple myeloma. Just prior to joining Karyopharm, Dr. Sayad led the global medical affairs and business development organizations at the International Myeloma Foundation (IMF) as SVP, Global Medical Affairs and Strategic Partnerships.
Dr. Sayad earned his undergraduate degrees from San Jose State University and holds Bachelor of Science degrees in Molecular Physiology and Psychology, and a Bachelor of Arts in Music. He completed his graduate work at the School of Medicine, Loma Linda University achieving Master of Science degrees in Molecular Physiology and BioMedical Sciences. Dr. Sayad completed his graduate work in the field of multiple myeloma and holds a Doctor of Philosophy in Psychoneuroimmunology (PNI).